官方服务：
资源简介：
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
应用场景：
创建时间：
2022-09-01
相关数据集
Additional file 6 of Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts
Additional file 5: Tables S5A–B. Differentially expressed genes in MaMel21 and MaMel63a treated with 2 µM of vemurafenib, in comparison to DMSO control.
Figshare2021-12-20 更新70
Gene expression in Vemurafenib-treated A375 and A2058 melanoma cell lines
Human melanoma cell line A375 and A2058 were incubated with DMSO (control group) or Vemurafenib (1 μM in DMSO) for 72 hours. Total RNA was isolated with Qiagen RNA isolation kit; 1.5 μg of total RNA w
NIAID Data Ecosystem50
Melanoma tissue samples from a clinical trial: no treatment vs. post-temsirolimus alone vs. post-combination temsirolimus and bevacizumab
To determine if treatment with a combined therapeutic regimen, which resulted in clinical benefit in a subset of patients in a clinical trial, alters miRNA expression in a way that may be used to guid
NIAID Data Ecosystem30
ChIPseq analysis of changes in binding of TFCP2L1 antibody in B16F0 cells in response to SX-682 treatment.. ChIPseq analysis of changes in binding of TFCP2L1 antibody in B16F0 cells in response to SX-682 treatment.
To define the activity of TFCP2L1 following CXCR2 perturbation, we performed chromatin immunoprecipitation and sequencing analysis (CHIPseq) on B16F0 tumorigenic melanoma cells following treatment wit
NIAID Data Ecosystem50
A375 melanoma cells treated with leflunomide 25uM
Human A375 melanoma cells were treated with leflunomide 25uM for 3 days, then RNA harvested 6 arrays
NIAID Data Ecosystem50
